Precision Medicine

Precision Medicine

New predictive models are key to building the bridge between clinical trials and precision medicine.

Our Thinking

The applications surrounding more personalized approaches to prevention and treatment are endless, but collecting the necessary clinical data can present conceptual and practical challenges. At the DCRI, researchers are collaboratively developing registries, research programs, and partnerships in service of personalized medicine. Working together, we can transform the way conditions such as cancer and heart disease are treated.

Kristin Newby, MD, MHS
Professor of Medicine, Cardiology

"What if we tailored disease therapies and prevention to each individual’s unique environmental, sociocultural and biological profile?"




Michael Pencina and Jessie Tenenbaum on Data and Biomarkers


Michael Pencina, PhD, and Jessie Tenenbaum, PhD, discuss how data and biomarkers inform the DCRI’s approach to precision medicine.

Kristin Newby on the MURDOCK Study


Kristin Newby, MD, MHS, principal investigator for the MURDOCK Study, discusses how the study is the next step in understanding diseases at a genetic level.


Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.


Comment on Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

Collaboration: The MURDOCK Study

The MURDOCK Study, or the Measurement to Understand the Reclassification of Disease of Cabarrus/Kannapolis, is Duke University’s longitudinal health study working to reclassify health and disease through advanced scientific technologies, expertise from Duke researchers, and close collaboration with our strong network of local and regional community partners.

logo, murdock study


Bray Patrick-Lake, MFS
Precision Medicine Initiative

Bray Patrick-LakeBray Patrick-Lake supports efforts to actively engage participant partners in Duke University’s research programs, as well as patient advocacy organizations and other stakeholders in Clinical Trials Transformation Initiative (CTTI) efforts to improve clinical trials. She implements strategies to enhance awareness of Duke’s Clinical and Translational Science Awards (CTSA) and CTTI’s work, particularly with patient advocates, and extend its impact by working in partnership with the patient advocacy community on research design and conduct and improvement of the clinical trial enterprise.

In this video, Bray Patrick-Lake talks about how the Precision Medicine Initiative will help unify medical records and treat individuals instead of averages.